![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SLC38A9 |
Gene summary for SLC38A9 |
![]() |
Gene information | Species | Human | Gene symbol | SLC38A9 | Gene ID | 153129 |
Gene name | solute carrier family 38 member 9 | |
Gene Alias | URLC11 | |
Cytomap | 5q11.2 | |
Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | Q8NBW4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
153129 | SLC38A9 | CCI_2 | Human | Cervix | CC | 1.58e-06 | 6.48e-01 | 0.5249 |
153129 | SLC38A9 | CCI_3 | Human | Cervix | CC | 3.74e-11 | 6.38e-01 | 0.516 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Cervix | ![]() | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
N_HPV: HPV-infected normal cervix |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00011016 | Cervix | CC | response to acid chemical | 31/2311 | 135/18723 | 4.16e-04 | 4.22e-03 | 31 |
GO:00712292 | Cervix | CC | cellular response to acid chemical | 20/2311 | 80/18723 | 1.40e-03 | 1.10e-02 | 20 |
GO:00712301 | Cervix | CC | cellular response to amino acid stimulus | 18/2311 | 71/18723 | 2.01e-03 | 1.47e-02 | 18 |
GO:00432004 | Cervix | CC | response to amino acid | 25/2311 | 116/18723 | 3.59e-03 | 2.30e-02 | 25 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC38A9 | SNV | Missense_Mutation | c.895C>T | p.Leu299Phe | p.L299F | Q8NBW4 | protein_coding | tolerated(0.07) | probably_damaging(0.939) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
SLC38A9 | insertion | Nonsense_Mutation | novel | c.1062_1063insGGACATGGATGAAATTGGAAATCACCGTTCTCAGTAAACT | p.Ile355GlyfsTer4 | p.I355Gfs*4 | Q8NBW4 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
SLC38A9 | SNV | Missense_Mutation | novel | c.1403G>A | p.Gly468Asp | p.G468D | Q8NBW4 | protein_coding | tolerated(0.2) | possibly_damaging(0.81) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC38A9 | SNV | Missense_Mutation | c.803N>G | p.Ser268Cys | p.S268C | Q8NBW4 | protein_coding | tolerated(0.11) | benign(0.43) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
SLC38A9 | SNV | Missense_Mutation | novel | c.1054N>T | p.Val352Leu | p.V352L | Q8NBW4 | protein_coding | deleterious(0.02) | possibly_damaging(0.877) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLC38A9 | SNV | Missense_Mutation | c.1555T>A | p.Phe519Ile | p.F519I | Q8NBW4 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SLC38A9 | SNV | Missense_Mutation | c.127G>A | p.Glu43Lys | p.E43K | Q8NBW4 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SLC38A9 | SNV | Missense_Mutation | novel | c.1050N>G | p.Phe350Leu | p.F350L | Q8NBW4 | protein_coding | tolerated(0.26) | benign(0.005) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SLC38A9 | SNV | Missense_Mutation | rs759238694 | c.530N>T | p.Ser177Leu | p.S177L | Q8NBW4 | protein_coding | tolerated(0.4) | benign(0.003) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
SLC38A9 | SNV | Missense_Mutation | novel | c.1109N>G | p.Phe370Cys | p.F370C | Q8NBW4 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |